Future study may focus on the combinatory treat of vemurafenib-resistant melanoma by targeting both of LINC01198 and IL-1β may also endorse promising for improving cancer treatment efficacy and tackle down vemurafenib resistance. The gene discussed is IL1B; the disease is melanoma.